Pacritinib Effectiveness in Real-world Settings

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Swedish Orphan Biovitrum
Study ID
NCT07774455
Status
Recruiting
Apply to this trial

Conditions

  • Myelofibrosis (MF)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Not applicable- observational study — OTHER
    Not Applicable - Observational Study

Study Details

This study aims to evaluate real-world treatment patterns and effectiveness of pacritinib, including hematologic and clinical outcomes, and survival through a site-based retrospective chart review of medical records of patients with MF.

Key Dates

First listed
Aug 19, 2026
Start date
Aug 13, 2026
Status verified
Sep 2026
Primary completion
Jan 27, 2027
Completion
Jan 27, 2027

Study Design

Enrollment
60 participants (estimated)

Primary Outcome Measure

≥50% spleen length reduction [ Time Frame: From the Index Date to Week 24 or best response in spleen reduction, assessed up to 49 months. ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Yale School of MedicineNew HavenConnecticut06511
The Ohio State UniversityColumbusOhio43210
Srisuwananukorn
[email protected]
Medical University of South CarolinaCharlestonSouth Carolina29425

Find similar trials in New Haven, CT

By research site
Yale School of Medicine· New Haven, CTThe Ohio State University· Columbus, OHMedical University of South Carolina· Charleston, SC

Related Studies